Cargando…

Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children

BACKGROUND: We conducted a trial in Nigeria to assess the immunogenicity of the new bivalent oral poliovirus vaccine + inactivated poliovirus vaccine (bOPV+IPV) immunization schedule and gains in type 2 immunity with addition of second dose of IPV. The trial was conducted in August 2016–March 2017,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tagbo, Beckie N, Verma, Harish, Mahmud, Zubairu M, Ernest, Kolade, Nnani, Roosevelt O, Chukwubike, Chinedu, Craig, Kehinde T, Hamisu, Abdullahi, Weldon, William C, Oberste, Steven M, Jeyaseelan, Visalakshi, Braka, Fiona, Mkanda, Pascal, Esangbedo, Dorothy, Olowu, Adebiyi, Nwaze, Eric, Sutter, Roland W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189759/ https://www.ncbi.nlm.nih.gov/pubmed/33230550 http://dx.doi.org/10.1093/infdis/jiaa726

Ejemplares similares

Poliovirus seroprevalence before and after interruption of poliovirus transmission in Kano State, Nigeria
por: Iliyasu, Zubairu, et al.
Publicado: (2016)

Trends in Poliovirus Seroprevalence in Kano State, Northern Nigeria
por: Verma, Harish, et al.
Publicado: (2018)

Fecal Shedding of 2 Novel Live Attenuated Oral Poliovirus Type 2 Vaccine Candidates by Healthy Infants Administered Bivalent Oral Poliovirus Vaccine/Inactivated Poliovirus Vaccine: 2 Randomized Clinical Trials( )
por: Gast, Christopher, et al.
Publicado: (2021)

Assessment of poliovirus antibody seroprevalence in high risk areas for vaccine derived poliovirus transmission in Madagascar
por: Razafindratsimandresy, Richter, et al.
Publicado: (2018)

Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine — Worldwide, 2013–2016
Publicado: (2015)

Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
por: Resik, Sonia, et al.
Publicado: (2018)

Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States
por: Marin, Mona, et al.
Publicado: (2017)

A Survey to Assess Serological Prevalence of Poliovirus Antibodies in Areas With High-Risk for Vaccine-Derived Poliovirus Transmission in Chad
por: Gamougam, Kadidja, et al.
Publicado: (2021)

Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Survey of poliovirus antibodies in Borno and Yobe States, North-Eastern Nigeria
por: Gofama, Mustapha Modu, et al.
Publicado: (2017)

Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China
por: Hu, Yuemei, et al.
Publicado: (2019)

Immunogenicity of Reduced-Dose Monovalent Type 2 Oral Poliovirus Vaccine in Mocuba, Mozambique
por: de Deus, Nilsa, et al.
Publicado: (2020)

Inactivated Poliovirus Vaccine Closing the Type 2 Immunity Gap in Vietnam
por: Huyen, Dang Thi Thanh, et al.
Publicado: (2022)

A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2020)

Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: a pragmatic, open-label, non-inferiority trial in The Gambia
por: Bashorun, Adedapo O, et al.
Publicado: (2021)

The Switch From Trivalent to Bivalent Oral Poliovirus Vaccine in the South-East Asia Region
por: Bahl, Sunil, et al.
Publicado: (2017)

Seroprevalence of Poliovirus Antibodies in the United States Population, 2009–2010
por: Wallace, Gregory S., et al.
Publicado: (2016)

Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies
por: Resik, Sonia, et al.
Publicado: (2015)

The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines
por: Jia, Siyue, et al.
Publicado: (2020)

Immunogenicity of Fractional Dose Inactivated Poliovirus Vaccine in India
por: Ahmad, Mohammad, et al.
Publicado: (2021)

The Case for Live Poliovirus Vaccination
por: Paul, John R.
Publicado: (1960)

Towards an effective poliovirus laboratory containment strategy in Nigeria
por: Ticha, Johnson Muluh, et al.
Publicado: (2018)

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Cold chain and virus‐free chloroplast‐made booster vaccine to confer immunity against different poliovirus serotypes
por: Chan, Hui‐Ting, et al.
Publicado: (2016)

Preventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame
por: Pons-Salort, Margarita, et al.
Publicado: (2016)

Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region
por: Tevi-Benissan, Carol, et al.
Publicado: (2017)

Immunogenicity of poliovirus vaccines in chronically malnourished infants: A randomized controlled trial in Pakistan
por: Saleem, Ali Faisal, et al.
Publicado: (2015)

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials
por: Sáez-Llorens, Xavier, et al.
Publicado: (2021)

One Full or Two Fractional Doses of Inactivated Poliovirus Vaccine for Catch-up Vaccination in Older Infants: A Randomized Clinical Trial in Bangladesh( )
por: Aziz, Asma B, et al.
Publicado: (2022)

Recombinant Vaccine–Derived Poliovirus in Madagascar
por: Rousset, Dominique, et al.
Publicado: (2003)

Vaccine–derived Poliovirus, Thailand, 2003
por: Tharmaphornpilas, Piyanit
Publicado: (2005)

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials
por: De Coster, Ilse, et al.
Publicado: (2021)

Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization
por: Sarnquist, Clea, et al.
Publicado: (2018)

Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan
por: Saleem, Ali Faisal, et al.
Publicado: (2017)

Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal()
por: Harutyunyan, Vachagan, et al.
Publicado: (2023)

Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy
por: DUINTJER TEBBENS, R. J., et al.
Publicado: (2017)

Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2018)

Poliomyelitis seroprevalence in high risk populations of India before the trivalent-bivalent oral poliovirus vaccine switch in 2016
por: Ahmad, Mohammad, et al.
Publicado: (2021)

The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission
por: Thompson, Kimberly M., et al.
Publicado: (2015)

Achieving High Poliovirus Antibody Seroprevalence in Areas at Risk of Vaccine-Derived Poliovirus Transmission—Niger Experience
por: Ousmane, Sani, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jt98aikt0m1cobevbgubql5abv